Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update

MarketResearchReports.Biz presents this most up-to-date research on "Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update"

This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target. The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 – 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R). Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan/MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia, Cyramza, Perjeta, Arrzera are also subject of biosimilar activities.

The report also addresses the slowly emerging second wave of biosimilar antibody activities against originator therapeutic antibodies such as abatacept, alemtuzumab, denosumab, eculizumab, omalizumab, pavilizumab, tocilizumab, and ustekinumab.

Get The Sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/724046

Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target/Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Content

A) 2015 SALES OF THERAPEUTIC ANTIBODIES

Overview: 2015 Biologics Sales per Class of Products
Overview: 2015 Therapeutic Antibody Sales per Class of Products
Blockbuster Therapeutic Antibodies in 2015
Anti-TNF Antibody Sales in 2015
Cancer Antibody Sales in 2015
Other Anti-Inflammatory Antibody Sales in 2015
Ophthalmic Antibody Sales in 2015
Cardiometabolic & Anti-Infective Antibody Sales in 2015

B) BIOSIMILAR AND BIOSUPERIOR ANTI-TNF ANTIBODIES – 2016 UPDATE

1. Originator Anti-TNF Antibodies
Approved and Marketed Indications of anti-TNF Antibodies in Regulated Markets
2015 SALES OF ANTI-TNF ANTIBODIES
Sales of Anti-TNF Antibodies in Q1/2016
Humira Pipeline of Recently Approved Indications & Upside Developments
Remicade Pipeline of Recent Approvals & Upside Indications
Enbrel Pipeline of Upside Indications
Simponi Pipeline of Recent Approvals & Upside Indications
Cimzia Pipeline of Recent Approvals & Upside Indications
Defense Strategies against Biosimilar Anti-TNF Antibodies
2. Biosuperior Anti-TNF Antibodies
Non-Antibody Anti-TNF Biosuperiors
Anti-TNF Biosuperior Antibodies
3. Biosimimilar Anti-TNF Antibodies
Humira Biosimilar Antibodies:
Developments in Regulated Markets
Developments in Less Regulated Markets
Enbrel Biosimilar Antibodies:
Developments in Regulated Markets
Developments in Less Regulated Markets
Remicade Biosimilar Antibodies:
Developments in Regulated Markets
Developments in Less Regulated Market
Simponi & Cimzia Biosimilar Antibodies

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

To View The Latest Industry Press Releases: http://www.marketresearchreports.biz/pressreleases

Contact
Tel: +1-518-621-2074
E-Mail: sales@marketresearchreports.biz
Website: http://www.marketresearchreports.biz/

MarketResearchReports.biz supports your business intelligence needs with over 100,000 market research reports, company profiles, data books, and regional market data sheets in its repository. Our document database is updated by the hour, which means that you always have access to fresh data spanning over 300 industries and their sub-segments.

State Tower
90 State Street, Suite 700
Albany, NY 12207
United States

Toll Free: 866-997-4948
(USA-CANADA)

Tel: +1-518-621-2074
E: sales@marketresearchreports.biz

This release was published on openPR.